Two of three patients achieved both complete remission and MRD-negative status
High response rates observed in earlier studies continue in ongoing mipletamig trial
Cohort 2 enrollment commencing
Read MoreDeveloping innovative bispecific antibodies for monotherapy and combination with the potential to expand the frontiers of cancer treatment
Read More